Clinical Trial Update: Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS) [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating safety and efficacy of orally administered laquinimod versus placebo in relapsing-remitting multiple sclerosis completed with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Laquinimod (laquinimod)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2021-11-02